BHCM
ORMP icon

Boulder Hill Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Boulder Hill Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-38,600
Closed -$551K – 211
2021
Q4 		$551K Buy
+38,600
New +$807K 0.53% 68

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Boulder Hill Capital Management's ORMP Position: Q1 2022 in Review

Boulder Hill Capital Management sold out of Oramed Pharmaceuticals (ORMP) in Q1 2022, closing a stake of 38,600 shares — an estimated $551K sold.

Boulder Hill Capital Management first reported a position in ORMP in Q4 2021 and held it in 1 quarter. The position peaked at $551K in Q4 2021. 103 funds tracked by Wall St. Rank hold ORMP as of Q1 2022.

  • Boulder Hill Capital Management reported no remaining Oramed Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Boulder Hill Capital Management sold 38,600 Oramed Pharmaceuticals shares in Q1 2022, an estimated $551K.
  • Boulder Hill Capital Management first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Boulder Hill Capital Management's Oramed Pharmaceuticals position peaked at $551K in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2022.

Based on Boulder Hill Capital Management's 13F filing for Q1 2022, filed 12 May 2022.